Published: Feb 22, 2012 02:00 AM
Modified: Feb 20, 2012 10:41 PM
Carrboro man to get stem cell transplant
Treatment a first at UNC
BY ELIZABETH SWARINGEN, Special to The Chapel Hill News
CHAPEL HILL - Three infusions of your own stem cells - each infusion over a 21-day hospitalization - can seem daunting. But, when it's your best chance for beating a recurrence of testicular cancer, you look forward to it."It doesn't seem intimidating to me at all," said David Alston, 42, of Carrboro. "You don't normally think of stem cell bone marrow transplants as treatment for testicular cancer, but it has been done in New York with success. I'm pleased it's available to me here at UNC Hospitals."This month Alston is having the first triple-tandem transplant done in an adult at UNC Hospitals.The process involves harvesting and freezing his own stem cells, receiving high-dose chemotherapy to attack the cancer, then having the stem cells infused over three back-to-back hospitalizations."He's young and otherwise healthy, and we think this is the right thing for him," said Dr. Paul M. Armistead, assistant professor of medicine in the Division of Hematology/Oncology, a member of the UNC Lineberger Comprehensive Cancer Center and leader of Alston's transplant team. "This is his best chance for being cured."Alston, a Charlotte native, was diagnosed with aggressive testicular cancer in March 2011 after experiencing an "avalanche of symptoms.""I didn't have a lump, but I had some weird back pain and loss of feeling in one leg," David said. "By the time I had some scans, we found lymph node involvement in a lot of places. Essentially, the cancer had gone on vacation all over my body."Testicular cancer is one of the more curable cancers, often cured in the first round of chemotherapy, said Dr. Kim Rathmell, associate professor of medicine, a member of UNC Lineberger Comprehensive Cancer Center and Alston's medical oncologist.Aggressive chemotherapy sent the cancer into remission, and by August Alston returned to his long-time job at Weaver Street Market in Chapel Hill's Southern Village.Routine blood test results in December surprised everyone: the cancer was back."Because of the way David's cancer came back, a more aggressive approach than chemotherapy alone was needed," said Rathmell, adding how hard it was knowing Alston faced treatment again. "I shop that store, and I had seen him back at work."Dr. Matthew Milowsky, who participated in the development of the triple-tandem transplant for testicular cancer at Memorial Sloan Kettering in New York City, joined UNC Lineberger Comprehensive Cancer Center last fall as co-director of UNC's urologic oncology program. Rathmell quickly recruited him to Alston's team."We have everything we need here at UNC to treat David," Rathmell said. "Had David come to us five years ago, when this recommended treatment was newer and we didn't have local expertise, I would likely have referred him elsewhere. Today, we are very comfortable doing this transplant here. And it's a total team approach."In January, Alston began receiving two types of chemotherapy to mobilize his stem cells in preparation for collection.This chemotherapy featured one less drug than what he endured after initial diagnosis and yielded fewer side effects."It was night and day difference," he said, remembering the physical and mental side effects that sent him into the ICU last spring. "By comparison, what I'm doing in preparation for the transplant has been rather effortless."But the process is complicated and has many moving parts."David will have five chemotherapy infusions administered by two separate medical teams that have to work together through a lot of logistics about what happens when," said Armistead. "That David is organized and intelligent and sends a lot of questions to Dr. Rathmell and me via email, he's helping himself stay on top of things. Having a patient who is fully aware of what's going on has kept us on our toes and helped us develop and coordinate a more fool-proof system."Still, as a single, stubbornly independent man, Alston needed help and support. Luckily, his mother, Barbara Alston, a retired medical professional from Concord, is by his side.Both are staying at SECU Family House, the 40-bedroom hospital hospitality house minutes from UNC Hospitals for seriously ill adult patients and their family member caregivers.The Alstons will stay at Family House during the nine weeks total that David is expected to be hospitalized. He will join her between transplants and for post-transplant monitoring."It's a comfort being here at Family House," Barbara Alston said. "If we need something, it's taken care of, both here and at the hospital. I'm assured David's getting the care he needs. I'm helping him whenever and wherever I can."SECU Family House will play an even larger role in Alston's recovery post-transplant, both Rathmell and Armistead agreed."This treatment is intense, and David will be more in the hospital than out," Rathmell said. "He will need a solid support system, and he has that with his mother. It's a fragile time, and she has his best interest at heart.""Post-transplant David will need to be monitored closely because his immune system will be very weak," Armistead said. "His mother's medical background is a bonus. The Family House folks are used to immune-suppressed patients and can get them to the hospital quickly if needed."Alston has kept himself swimming in information to minimize the fear and mystery. Barbara has been the great translator when his own efforts didn't yield the level of detail he needed."The constant learning gives it all a degree of routine that took some of the scariness away," Alston said. "But you can't be too independent or too brainy when you have cancer."Cancer blows you out of the water, but it leaves you with valuable insight," he said. "How you deal with cancer is self-guided and you learn things about yourself and your personality that you never knew. It's the ultimate in snatching the silver lining from a cloud."
Elizabeth Swaringen wrote this article for UNC Health Care.
See the rest here:
Carrboro man to get stem cell transplant
- Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed... - November 22nd, 2021
- Researcher awarded $12 million for a stem cell trial to improve outcomes of young blood cancer patients - Stanford Medical Center Report - November 8th, 2021
- Heart Tissue in a Dish Reveals New Links Between Neurodegeneration and Heart Disease - PRNewswire - November 8th, 2021
- Vaccines less effective at protecting against severe COVID-19 in immunocompromised adults - EurekAlert - November 8th, 2021
- Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA in the 340B Hospital Setting Through Year-End 2022 -... - November 8th, 2021
- Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy for Relapsed and... - November 8th, 2021
- All you need to know about the COVID boosters available in Somerset County - Daily American Online - November 8th, 2021
- Asia-Pacific Cell Therapy Market 2021-2028 - Opportunities in the Approval of Kymriah and Yescarta - PRNewswire - August 5th, 2021
- Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of ... - The Bakersfield Californian - August 5th, 2021
- IDH1 Inhibitors, CAR T-Cell Therapy, and Third-Generation TKIs Refresh Relapsed/Refractory Leukemia Landscape - OncLive - August 5th, 2021
- Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients -... - August 5th, 2021
- Is This Small-Cap Biotech a Buy After Its Second Approved Gene Therapy? - Motley Fool - August 5th, 2021
- Defining Cell Culture Lines and Media - The Scientist - August 5th, 2021
- Preimplantation Genetic Testing Demand to Grow by 9% CAGR Annually, through 2031 - BioSpace - August 5th, 2021
- Cell Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com - Business Wire - July 7th, 2021
- A New Era For FDA Regulation Of Cell And Tissue Products - Law360 - July 7th, 2021
- UM School Of Medicine Researchers Receive NIH Avant Garde Award For Out-Of-Box, Innovative Concept To Cure HIV And Treat Co-Existing Addiction -... - July 7th, 2021
- Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of... - July 7th, 2021
- The Top Doctors in the Twin Cities, 2021 - Mpls.St.Paul Magazine - July 7th, 2021
- The stem cell market was valued at USD 14.7 billion in 2020, and it is expected - GlobeNewswire - June 8th, 2021
- Innovative Regenerative Medicine Therapies Safety Comes First - FDA.gov - June 8th, 2021
- Early Promise of AntiCLL-1 CAR T-Cell Therapy Reported in Pediatric AML - Cancer Network - June 8th, 2021
- Part 3: Moving Forward and Keeping Stem Cell Treatments Safe - MedShadow - June 8th, 2021
- In Some Heavily Pretreated Patients with R/R MM Ide-Cel Continues to Show Deep and Durable Responses - Targeted Oncology - June 8th, 2021
- Innovative research refines the treatment of patients with advanced cancers and the use of immunotherapy - Network News, Press Releases - Hackensack... - June 8th, 2021
- Mustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic... - June 8th, 2021
- Karen Hasty Named Among 2021 Super Women In Business by Memphis Business Journal - UTHSC News - June 8th, 2021
- High Overall Response Rates Achieved With Cirmtuzumab/Ibrutinib in MCL and CLL - Targeted Oncology - June 8th, 2021
- New Data on KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell... - June 8th, 2021
- Chao family gifts to UCI Health for cancer care top $50 million - UCI News - June 8th, 2021
- Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric - GlobeNewswire - June 8th, 2021
- Responses to Tafasitamab/Lenalidomide in DLBCL Sustained at Three Years - Cancer Network - June 8th, 2021
- The regenerative medicine market size to grow at a CAGR of around 30% during the period - GlobeNewswire - June 8th, 2021
- 'Natural Killer Cells' and Other Promising Cancer Treatments - Barron's - April 18th, 2021
- Capturing the Pandemic Experience in Haiku Poetry - Duke Today - April 18th, 2021
- Chemotherapy for Prostate Cancer: When It's Used and What to Expect - Healthline - April 18th, 2021
- Signs that Chemo Is Working: How Effectiveness Is Measured and Defined - Healthline - April 18th, 2021
- Some experts fear next-generation Covid vaccines may be worse - STAT - April 18th, 2021
- How Long is Chemotherapy? What to Expect - Healthline - April 18th, 2021
- Regenerative Medicine - Stem Cell Therapy Little Rock - March 8th, 2021
- Center for Stem Cell Biology & Regenerative Medicine ... - March 8th, 2021
- Dynamic Stem Cell Therapy Offers Regenerative Medicine - Las Vegas Review-Journal - March 8th, 2021
- Anti-EGFR VHH-armed death receptor ligandengineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers -... - March 8th, 2021
- Research Antibodies Market Size to Reach USD 5325.8 Million by 2027 | Increasing R&D; Activities in the Fields of Oncology, Neurobiology, and Stem... - March 8th, 2021
- Microwave Processing Isolates Red Ginseng Compounds That Suppress Lung Cancer Metastasis - Genetic Engineering & Biotechnology News - March 8th, 2021
- Longeveron Expands Enrollment Criteria for its Phase 1 RECOVER Trial Evaluating Lomecel-B Infusion to Treat Acute Respiratory Distress Syndrome due to... - March 8th, 2021
- Be The Match BioTherapies Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of... - March 8th, 2021
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2021: Focuses at the key worldwide companies to Define, Describe and Analyses the sales... - March 8th, 2021
- Editing Reproduction: CRISPR and preventing heritable diseases, With Dr. Dietrich Egli and Dr. Sam Sternberg - Columbia University Irving Medical... - March 8th, 2021
- U. Cancer Center pilot projects: investigating cancer connections - The Brown Daily Herald - March 8th, 2021
- COVID-19 can kill heart muscle cells, interfere with contraction Washington University School of Medicine in St. Louis - Washington University School... - March 8th, 2021
- Vaccinating by age groups is unfair, particularly to minorities, advisory panel tells CDC - USA TODAY - March 8th, 2021
- Winter Weather Impacting Blood and Platelet Donations - Milwaukee Community Journal - February 17th, 2021
- Joshua Shirk continues to fight the odds; mom says God placed people where they needed to be to help him - Keyser Mineral Daily News Tribune - February 17th, 2021
- Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy for Heart Failure - GuruFocus.com - February 7th, 2021
- ProgenCell - Stem Cell Therapies offers an updated Stem Cell Therapy for Anti Aging Protocol - PR Web - January 30th, 2021
- Doctors urge immunocompromised to get COVID vaccine when it becomes available - KMTV - 3 News Now - January 30th, 2021
- Autologous Stem Cell and Non Stem Based therapies Market Share, Size 2021 Global Industry Future Trends, Growth, Strategies,, Segmentation, In-depth... - January 30th, 2021
- Studies Indicating T-Cells May Be Needed For Long-Term Protection From The SARS-Cov-2 Virus - PRNewswire - January 30th, 2021
- Researchers use patients' cells to test gene therapy for rare eye disease - National Institutes of Health - January 30th, 2021
- Two Gene Therapies Fix Fault in Sickle Cell Disease and -thalassemia - MD Magazine - January 30th, 2021
- If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine? - Kaiser Health News - January 30th, 2021
- L-MIND Trial Results Show CD19 Antibody Is Reasonable in R/R DLBCL - Targeted Oncology - January 30th, 2021
- Profile of T Cells, Broadly Neutralizing Antibodies, Anti-Viral Targets: COVID-19 Updates - Bio-IT World - January 30th, 2021
- HealthLynked's The Future of Healthcare Summit Brings Healthcare Experts and Technology Innovators from Around the World to Naples, Florida - WFMZ... - January 30th, 2021
- Tevogen Bio Secures Funding from Team of Doctors to Support Clinical Trials of Its Investigational Curative T Cell Therapy for COVID-19 - PRNewswire - January 25th, 2021
- Novel Treatment Leads to Dog's Recovery - The Bark - January 25th, 2021
- Identification and Targeting of ThomsenFriedenreich and IL1RAP | OTT - Dove Medical Press - January 25th, 2021
- Regenerative Medicine Market Size Worth $74831.35 Million With CAGR of 22.27% By 2024 | Segmented by Product Type, Top Manufacturers, By End-User... - January 25th, 2021
- Immunotherapy Inches Forward in Development of Myeloid Malignancies - OncLive - January 14th, 2021
- Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for the Treatment of Solid... - January 14th, 2021
- Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19 - BioSpace - January 14th, 2021
- Doctors Make Medical Breakthrough In Treating Severe Cases Of COVID - CBS San Francisco - January 9th, 2021
- Mana joins the hectic fight against solid tumors with an 'off-the-shelf' candidate angling for an IND this year - Endpoints News - January 9th, 2021
- Versiti Blood Centers and Noodles & Company Serve Up Thanks to Blood Donors - PRNewswire - December 31st, 2020
- Global CAR-T Pipeline Insight Report 2020: Overview, Landscape, Therapeutic Assessment, Current Treatment Scenario and Emerging Therapies -... - December 31st, 2020
- 2020 health care year in review - Crain's Cleveland Business - December 31st, 2020
- The Top 10 FDA Oncology Drug Approvals of 2020 - Curetoday.com - December 31st, 2020
- Gut microbiota: How does it interact with the brain? - Medical News Today - December 31st, 2020
- Numerous Indian American STEM Researchers Named Fellows of American Association for the Advancement of Sciences - India West - December 31st, 2020
